According to statistical data from the "Pharmaceutical Industry Market Foresight and Investment Strategic Planning Analysis Report" released by the Qianzhan Industry Research Institute, the pharmaceutical manufacturing industry achieved a main business income of 1820.37 billion yuan from 1 to September 2008, a year-on-year increase of 1 3.6%. The total profit was 230.59 billion yuan, a year-on-year increase of 11.5%. During the same period, the revenue growth rate and profit growth rate of listed pharmaceutical companies were 21.79% and 20.14% respectively.
In terms of quarters, the pharmaceutical manufacturing industry achieved main business income of 562.64 billion yuan from July to September in 2008, a year-on-year increase of 13.6%; it achieved a total profit of 72.02 billion yuan, a year-on-year increase of 5.7%. During the same period, the revenue growth rate and profit growth rate of listed pharmaceutical companies were 21.23% and 9.46% respectively, which were higher than the overall pharmaceutical manufacturing industry.
Main business income, total profit statistics and growth of China's pharmaceutical industry from 1 to September 2008
Data source: Compiled by Qianzhan Industry Research Institute
From the perspective of the pharmaceutical industry, domestic aging, consumption upgrading, etc. have driven the demand market for the pharmaceutical industry to continue to be strong, and the demand for high-end products and services continues to increase. The pharmaceutical industry has entered a new business cycle, which will be dominated by innovative varieties, high-quality varieties, and high-quality enterprises.
At present, the policy direction is clear. Under the control of medical policies such as the reform of the review and approval system, the consistency evaluation of generic drugs, and the "two-invoice system", the industrial structure is tending to be optimized, the industry concentration continues to increase, and the strong will always be strong.
In the future, the pharmaceutical industry will move forward steadily in the incremental development of the industry brought about by structural optimization of the existing market and innovation-driven development. On the basis of maintaining steady growth in the pharmaceutical industry as a whole, leading companies are expected to enjoy the dividends brought by increased concentration and maintain Higher than the overall performance growth rate of the pharmaceutical manufacturing industry.
Analysis of development trends of pharmaceutical industry
1), market demand is growing steadily
From a global perspective, the growth rate of the pharmaceutical market in developed economies has rebounded, the demand in emerging pharmaceutical markets is strong, and the proportion of biotech drugs and chemical generic drugs in the medication mix has increased, bringing new opportunities to my country's pharmaceutical exports. Domestically, the national economy maintains medium-to-high growth, residents' disposable income increases and consumption structure upgrades, the construction of a healthy China is steadily advancing, the medical insurance system is further improved, the population ages and the implementation of the comprehensive two-child policy will continue to drive the rapid growth of the pharmaceutical market increase.
2), technological progress continues to accelerate
Precision medicine and translational medicine have provided a new direction for the development of new drugs and disease diagnosis and treatment. Innovative drugs based on new targets, new mechanisms and breakthrough technologies are constantly emerging, and the pace of transformation of new technologies such as tumor immunotherapy and cell therapy is accelerating. Medical devices are developing in the direction of intelligence, networking, and portability. New materials are widely used. The Internet and health big data are closely integrated with pharmaceutical products and medical services. Industrial upgrading and development have injected new impetus.
3). Industrial policies are more favorable
"Made in China 2025" lists biomedicine and high-performance medical devices as key development areas. The country continues to accelerate the cultivation of strategic emerging industries such as biomedicine as pillar industries of the national economy. Science and technology plans such as the "Major New Drug Creation" science and technology project continue to be implemented. It will provide strong policy support for improving the innovation capabilities, quality brands, intelligent manufacturing and green development levels of the pharmaceutical industry.
4). Industry supervision continues to be strengthened
The reform of the drug and medical device review and approval system has been fully implemented, drug registration classification has been adjusted, registration standards have been improved, review and approval speed has been accelerated, the drug marketing authorization holder system has been piloted, generic drug quality and efficacy consistency evaluation has been promoted, and the whole-process quality supervision has been strengthened. , will promote technological innovation, survival of the fittest and improvement of product quality. The implementation of the newly revised "Environmental Protection Law", the improvement of environmental protection standards and the strengthening of supervision and inspection have put forward higher requirements for the green development of the pharmaceutical industry.
5). Medical reform policies are constantly improving.
The reform of the medical and health system has been comprehensively deepened, the reform of public hospitals and the hierarchical diagnosis and treatment system have been accelerated, a market-led drug price formation mechanism has been gradually established, and a drug classification procurement policy based on the "double envelope" system, direct linking to the Internet, price negotiation, and designated production Full implementation, the gradual establishment of medical insurance payment standards, and the implementation of medical insurance fee control and comprehensive fee control measures for medical institutions will have a profound impact on the development trend and competitive landscape of the pharmaceutical industry.
Generally speaking, the pharmaceutical industry faces good development opportunities during the "Thirteenth Five-Year Plan" period. However, we must also note that developed countries are forming new competitive advantages by relying on technological changes and technological breakthroughs, and other emerging market countries have gained opportunities in the international competition of generic drugs; the early driving force supporting the rapid growth of my country's pharmaceutical industry is weakening, and various As constraints continue to strengthen and structural contradictions become more prominent, there is an urgent need to accelerate the conversion of new and old growth drivers. The sustained and healthy development of the pharmaceutical industry still faces many difficulties and challenges.